Literature DB >> 26271644

A suggestion for pathological grossing and reporting based on prognostic indicators of malignancies from a pooled analysis of renal epithelioid angiomyolipoma.

Shan Zheng1, Xin-gang Bi2, Qing-kun Song3,4, Zheng Yuan5, Lei Guo5, Hongtu Zhang6, Jian-hui Ma7.   

Abstract

PURPOSE: Epithelioid angiomyolipoma (EAML) is a rare entity of the kidney. The guideline for grossing and reporting of renal EAML has not been established for Chinese patients. We planned this study to provide some preliminary indicators for draft guidelines of pathological diagnosis among Chinese people.
METHODS: The histopathological characteristics of 11 EAML cases from Cancer Hospital, Chinese Academy of Medical Sciences, were reviewed, and a pooled analysis based on our cases and cases from published articles was performed on the histopathological characteristics and prognosis of 56 Chinese patients with EAML. All the cases met the criteria of the 2004 World Health Organization classification of renal tumors.
RESULTS: The ratio of female to male was 1.2:1 with the mean age of 43.4 in the 11 cases. All the 11 cases were sampled following the guideline of renal cell carcinoma. The mean tumor size was 6.5 cm. Four (36.4 %) cases showed necrosis. Six (54.5 %) cases showed invasive borders. Only one case showed metastases. In pooled analysis of the total 56 cases with EAML, 10 cases (17.9 %) showed adverse prognosis. Tumor size, necrosis and invasive edge showed significant difference between favorite and adverse prognostic groups (P < 0.05).
CONCLUSION: The majority of EAML is benign, and true malignant EAML is rare. The sample of EAML should follow the sample guidelines of renal cell carcinoma with some modifications, emphasizing the presence of necrosis and invading edge. The information of tumor size, necrosis and invasive edge should be included in the diagnostic report of each EAML case.

Entities:  

Keywords:  Angiomyolipoma; Epithelioid; Kidney; Pooled analysis; Prognosis

Mesh:

Year:  2015        PMID: 26271644     DOI: 10.1007/s11255-015-1079-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  25 in total

1.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

Review 2.  Renal epithelioid angiomyolipoma without obvious local progress in 10 years: a case report and literature review.

Authors:  J Wen; H-Z Li; Z G Ji; Q Z Mao; B B Shi; W G Yan
Journal:  Ir J Med Sci       Date:  2010-11-02       Impact factor: 1.568

3.  Epithelioid cell variant of renal angiomyolipoma.

Authors:  K T Mai; D G Perkins; J P Collins
Journal:  Histopathology       Date:  1996-03       Impact factor: 5.087

Review 4.  [Epithelioid angiomyolipoma of kidney: clinicopathologic study of two cases and review of literature].

Authors:  Yu-hong Meng; Fei Pei; Ping Lu; Ji-yao Yu; Jie Zheng
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2007-01

5.  Epithelioid angiomyolipoma with involvement of inferior vena cava as a tumor thrombus: a case report.

Authors:  Deyi Luo; Jiang Gou; Le Yang; Yong Xu; Qiang Dong
Journal:  Kaohsiung J Med Sci       Date:  2011-02       Impact factor: 2.744

6.  Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.

Authors:  Nalan Nese; Guido Martignoni; Christopher D Fletcher; Ruta Gupta; Chin-Chan Pan; Hyung Kim; Jae Y Ro; Il S Hwang; Katsuaki Sato; Franco Bonetti; Maurizio Pea; Mitual B Amin; Ondrej Hes; Alexandr Svec; Masatoshi Kida; Mahesha Vankalakunti; Dror Berel; Andre Rogatko; Allen M Gown; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

7.  Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma.

Authors:  M Pea; F Bonetti; G Martignoni; E P Henske; E Manfrin; C Colato; J Bernstein
Journal:  Am J Surg Pathol       Date:  1998-02       Impact factor: 6.394

8.  Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component.

Authors:  J N Eble; M B Amin; R H Young
Journal:  Am J Surg Pathol       Date:  1997-10       Impact factor: 6.394

9.  Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy.

Authors:  Fadi Brimo; Brian Robinson; Charles Guo; Ming Zhou; Matthieu Latour; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2010-05       Impact factor: 6.394

10.  Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: a clinicopathologic and genetic study.

Authors:  G Martignoni; M Pea; F Bonetti; G Zamboni; C Carbonara; L Longa; C Zancanaro; M Maran; M Brisigotti; G M Mariuzzi
Journal:  Am J Surg Pathol       Date:  1998-06       Impact factor: 6.394

View more
  3 in total

1.  Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study.

Authors:  Xin-Gang Bi; Lei Guo; Xiao-Liang Wang; Qian Wei; Qiang Du; Wen-Hao Jiang; Guang-Yuan Zheng; Hong-Tu Zhang; Jian-Hui Ma; Shan Zheng
Journal:  Oncol Lett       Date:  2017-05-29       Impact factor: 2.967

Review 2.  The Risks of Renal Angiomyolipoma: Reviewing the Evidence.

Authors:  Raouf M Seyam; Waleed K Alkhudair; Said A Kattan; Mohamed F Alotaibi; Hassan M Alzahrani; Waleed M Altaweel
Journal:  J Kidney Cancer VHL       Date:  2017-10-16

3.  ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study.

Authors:  Aihetaimujiang Anwaier; Wen-Hao Xu; Xi Tian; Tao Ding; Jia-Qi Su; Yue Wang; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  BMC Urol       Date:  2022-09-12       Impact factor: 2.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.